Agilent Webinar Series

The rapid expansion of peptide therapeutics, led by GLP-1 agonists, is increasing the need for analytical workflows that extend beyond individual techniques. Successful peptide development depends on designing integrated workflows that connect method development, characterization, and quality control across the lifecycle.

This session explores how such workflows are enabled through the combination of complementary separation technologies, mass spectrometry, and informatics within Agilent’s integrated analytical ecosystem. Attendees will gain insight into how end-to-end integration, from data generation to data management, supports consistent, compliant, and decision-ready peptide analysis as programs scale from research to manufacturing.

The rapid expansion of peptide therapeutics, led by GLP-1 agonists, is increasing the need for analytical workflows that extend beyond individual techniques. Successful peptide development depends on designing integrated workflows that connect method development, characterization, and quality control across the lifecycle. 

This session explores how such workflows are enabled through the combination of complementary separation technologies, mass spectrometry, and informatics within Agilent’s integrated analytical ecosystem. Attendees will gain insight into how end-to-end integration, from data generation to data management, supports consistent, compliant, and decision-ready peptide analysis as programs scale from research to manufacturing.

As GLP-1 peptide therapeutics advance through development, understanding how these molecules behave in biological systems becomes critical. Accurate measurement of GLP-1 analogs in plasma is essential for generating reliable pharmacokinetic and toxicokinetic data. This session explores bioanalytical workflows that combine automated sample cleanup with sensitive LC/MS-based quantitation to overcome the limitations of traditional antibody-based assays.

Attendees will learn how automation and mass spectrometry enable faster method development, improved specificity, and robust quantitation in complex biological matrices. The session highlights how bioanalysis strengthens development decisions by linking molecular design to in-vivo performance.

As GLP-1 analogs increase in structural complexity, efficient impurity profiling requires both speed and structural clarity. This session presents a staged LC/MS-based workflow that enables rapid impurity screening to identify candidates requiring deeper investigation, followed by targeted ECD-based sequence analysis for detailed structural insight. By separating fit-for-purpose screening from high-resolution characterization, the workflow reduces unnecessary analytical complexity and shortens the path from detection to interpretation. 

Attendees will learn how electron capture dissociation (ECD) preserves labile modifications, enabling precise localization and confident sequence confirmation. The session highlights how tiered impurity strategies support timely, data-driven decisions during GLP-1 development.

GLP-1 receptor agonists exhibit structural complexity and susceptibility to degradation, making robust impurity separation essential for quality control and regulatory compliance. This session highlights the use of orthogonal chromatographic approaches, reversed-phase liquid chromatography (RPLC) and hydrophilic interaction chromatography (HILIC), to improve impurity resolution and detection. 

Attendees will learn practical method development strategies, including gradient design, column selection, temperature control, and mobile phase optimization. The session demonstrates how combining orthogonal separations enhances confidence in impurity profiling and supports reliable characterization of GLP-1 analogs in development and QC environments.